MTOR and cancer: For instance, the co-administration of platycodin D with the mTOR inhibitor everolimus effectively terminated feedback reactivation of AKT, a well-documented resistance pathway that limits the efficacy of mTOR-targeted therapies.44 Collectively, the coordinated suppression of these signaling cascades contributes to robust and multifaceted antitumor activity, making Hsp90–Cdc37 PPI disruption a compelling strategy for cancer treatment.